Parkinson's disease Nervous System Diseases
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Clinically diagnosed with idiopathic Parkinson's disease 2. Classified between stage I-IV on Hoehn and Yahr (H&Y) classification scale during the clinical 'ON' state 3. Able to understand simple motor commands and of adequate cognition (screened using the Montreal Cognitive Assessment [MoCA]) 4. Able to walk 10 m without assistance 5. Regular use of and no change in antiparkinsonian medication in the last month 6. Aged 40-80 years
Exclusion criteria
Exclusion criteria: 1. Previously had deep-brain stimulation (DBS) surgery. 2. Presented with comorbidities that may affect movement patterns. 3. Presented with comorbidities that may affect their capacity to exercise. 4. Changed their medication type and/or dosage throughout the duration of the study. 5. Score poorly on the Falls Risk Assessment Tool (FRAT) and Falls Efficacy Scale - International (FES-I) assessment for fall risk. 6. Score poorly on the MoCA. 7. Investigator's determination of unsuitability for trial participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Axial rigidity measured using 3D motion capture at baseline, 4, 8, 12 and 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Gait kinematics measured using 3D motion capture at baseline, 4, 8, 12 and 24 weeks 2. Functionality measured using Timed-Up and Go (TUG), Functional Reach Test (FRT), Berg Balance Scale (BBS) and Five-Times Sit to Stand Test (FTSST) at baseline, 4, 8, 12 and 24 weeks 3. Postural balance during 30-second quiet stand using 3D motion capture at baseline, 4, 8, 12 and 24 weeks | — |
Countries
England, United Kingdom